Comparison of Glycemic Control With Smartphone Application
Comparison of Glycemic Control With Smartphone Application (Vivovitals) - Based Glucose Monitoring to Routine Home Glucose Monitoring in Poorly Controlled T2DM Patients Treated With Insulin
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Jamaica, New York, United States, 11432
- Queens Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult type 2 diabetes mellitus patients (≥ 18years of age) whose HbA1c is ≥8% on insulin.
- At least three months of daily home glucose monitoring before including in the study
- Willing to provide consent to participate in the study4. Uses a smartphone with cellular network and willing to and has ability to learn and use the Vivo vitals application on it.
Exclusion Criteria:
- Patients who have Gestational diabetes or type 1 diabetes
- Patients who have been admitted to the hospital in the last month for more than 3 days.
- Patients who have adrenal disorders or taking exogenous glucocorticoids.
- Patients who are mentally incompetent, having uncontrolled psychiatric conditions, inmates.
- Patients with active malignancies including those on treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Mobile application
Mobile application to enter glucose level
|
participants in intervention group will use smart phone application and update glucose level and investigator will adjust the insulin accordingly
Other Names:
|
|
PLACEBO_COMPARATOR: Daily Diary
Daily Diary to record glucose level
|
participants will use daily diary to record glucose level
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
HbA1c
Time Frame: at the end of 3 months follow-up
|
A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months.
It shows how well a person is controlling their blood sugar to help prevent complications from diabetes.
|
at the end of 3 months follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in weight
Time Frame: baseline and 3 month
|
Change in weight
|
baseline and 3 month
|
|
Change in Body Mass Index (BMI)
Time Frame: baseline and 3 month
|
Change in BMI
|
baseline and 3 month
|
|
Change in blood pressure
Time Frame: baseline and 3 month
|
Change in blood pressure - systolic and diastolic
|
baseline and 3 month
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Issac sachmechi, MD, FACE, FACP, Icahn School of Medicine Mount Sinai
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY-20-01694
- FWA#00005656 (OTHER: Department of Health and Human Services)
- FWA#00005651 (OTHER: Department of Health and Human Services)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.